Evidence map›Paper›PMID 40838678›Full record

ReviewAmerican journal of hematology2025

The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease.

Fnu Alnoor, Nicholas C Spies, Jyoti Kumar, Peyman Samghabadi, Oscar Silva, Matt X Luo, Karen M Chisholm, Jingjing Zhang, Alexandra Rangel, David Ng and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Clinical diagnosis and treatment of four cases of Castleman disease in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fnu AlnoorDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Nicholas C SpiesARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
Jyoti KumarDivision of Pathology, Department of Diagnostic Medicine, The University of Texas at Austin, Austin, Texas, USA.
Peyman SamghabadiDepartment of Pathology, University of California, San Francisco, California, USA.
Oscar SilvaDepartment of Pathology, Stanford University, Stanford, California, USA.
Matt X LuoDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-1740-0724
Karen M ChisholmDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-1898-1252
Jingjing ZhangUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Alexandra RangelDepartment of Pathology, University of California, San Francisco, California, USA.
David NgARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0001-8604-2073
Peng LiARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-4711-362X
Robert S OhgamiARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-1881-3440

Funding

Department of Pathology at the University of UtahRecordati Rare Diseases 080524
6 · The paper itself

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine-driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological, and molecular biomarker advancements. Key drivers of iMCD pathogenesis, such as interleukin-6 dysregulation and other dysfunctional cytokine signaling, have been identified and led to the development of targeted therapies like siltuximab and tocilizumab. Histopathologic refinements have highlighted distinct subtypes, such as hypervascular, plasmacytic, and mixed histologic patterns, while molecular discoveries have unveiled potential paraneoplastic and clonal processes. Emerging technologies, including single-cell sequencing, spatial transcriptomics, and digital pathology, offer promise in refining diagnostic precision and advancing personalized medicine. This review synthesizes historical frameworks, recent breakthroughs, and future directions in iMCD diagnostics, emphasizing the importance of multidisciplinary approaches for improved patient outcomes.

Indexed as

Castleman DiseaseAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersHumansInterleukin-6Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersInterleukin-6siltuximabtocilizumabCastleman diseasefibroblastic reticular cellsfollicular dendritic cellsidiopathic multicentric Castleman diseaseIgG4‐related diseaseinterleukin‐6

Identifiers

PMID40838678
PMCPMC12516665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.